Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
Revolution Medicines announced that detailed results from the pivotal Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer will be presented in a Plenary Session at the ASCO Annual Meeting. The topline results previously reported an unprecedented overall survival benefit, with statistically significant and clinically meaningful improvements in progression-free and overall survival compared to standard chemotherapy.
Key figures
- Drug Name
- Daraxonrasib
- Phase Of Trial
- Phase 3
- Us annual deaths
- 50000
- Daraxonrasib dose
- 300 mg
- Us annual diagnoses
- 60000
- Five year survival rate pct
- 3%
- Metastatic at diagnosis pct
- 80%
- Ras mutation prevalence pct
- 90%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.